Title

Therapeutic transformation for diabetic kidney disease.

Authors

Katherine Tuttle, Providence Medical Research Center, Providence Health Care, Spokane, Washington, USAFollow
David Z I Cherney

Document Type

Article

Publication Date

2-1-2021

Publication Title

Kidney international

Keywords

Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Glomerular Filtration Rate; Glucose; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; washington; spokane; PSHMC

Abstract

Risks of kidney failure and heart failure are markedly reduced by inhibition of the sodium glucose cotransporter 2 (SGLT2) in patients with diabetic kidney disease. In a post hoc analysis of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial, drop-in SGLT2 inhibitor usage during the atrasentan enrichment period led to greater reduction in albuminuria compared with atrasentan alone. These data support the hypothesis of greater longer-term kidney protection by combination SGLT2 inhibition and endothelin A receptor antagonism that could be tested in future clinical trials.

Clinical Institute

Kidney & Diabetes

Department

Nephrology

Department

Endocrinology

Recommended Citation

Tuttle, Katherine and Cherney, David Z I, "Therapeutic transformation for diabetic kidney disease." (2021). Articles, Abstracts, and Reports. 4296.
https://digitalcommons.providence.org/publications/4296